MedTrace Logo

To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer

NCT07195084 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-04-13

No results posted yet for this study

Summary

This study was a single-center, single-arm clinical study to evaluate the safety and efficacy of hypervision proton surgery with single large fractionated doses (34GyE and 39GyE) in the treatment of early peripheral NSCLC.

Conditions

Interventions

RADIATION

Hypervision proton surgery

Proton radiaotherapy (34GyE or 39GyE)

Sponsors & Collaborators

  • Anhui Provincial Hospital

    collaborator OTHER_GOV

  • Anhui Provincial Cancer Hospital

    lead OTHER

Principal Investigators

  • Shuanghu Yuan, PhD · Anhui Provincial Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-20
Primary Completion
2027-09-19
Completion
2028-09-19

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07195084 on ClinicalTrials.gov